The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

The maker of Ozempic is halving the price of its weight-loss jabs in the US after Donald Trump demanded cheaper drugs for ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Researchers urged caution, recommending that diabetic patients on GLP-1 therapies undergo regular eye screening….

Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from ...

Six in ten Brits (61 per cent) believe the correct modern etiquette is to call ahead of a dinner or lunch party - to notify ...

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.

Shares of Novo Nordisk (NVO) are rising early Monday after the US Food and Drug Administration approved Wegovy to treat ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Novo Nordisk shares (DK:NOVO.B) (NVO) rose 5% in opening New York trade. The American depository receipts however have plunged 37% this year amid increased competition for its weight-loss drugs as ...

In the first 24 hours after Lilly's announcement, Ozempic sales rose by 400 per cent, according to weight loss jab provider CheqUp.

MORE people than ever are taking weight loss jabs – but not everyone is seeing the same results. Experts now say that when you take these so-called ‘miracle’ drugs is key, impacting not only ...